endocrine · Mechanism Report
Does elevated free testosterone increase androgen signaling in tissues?
Elevated free testosterone increases androgen signaling because the unbound fraction can enter cells and activate androgen receptors.
This is what AI claimed
Free testosterone reflects the biologically active fraction of testosterone that can enter cells and activate androgen receptors, so elevated free testosterone increases androgen signaling in tissues.
Executive summary
The claim states that free testosterone is the biologically active fraction that diffuses into target cells, unlike SHBG-bound hormone. Once intracellular, it binds androgen receptors to trigger transcriptional signaling, and higher free levels produce dose-dependent increases in androgenic effects. The mechanism graph frames SHBG as inhibitory and links free testosterone → cellular entry → receptor activation → increased tissue signaling and clinical androgen excess.
Verified conclusion
In clinical endocrinology, the "free hormone hypothesis" remains the primary model for understanding hormone delivery, positing that only the unbound fraction of testosterone can exert biological effects.
Biological activity and cellular entry
Free testosterone is defined as the biologically active fraction because its unbound state allows it to leave the circulation and enter target cells.
- Passive Diffusion: Unlike testosterone bound to sex hormone-binding globulin (SHBG), which is restricted from crossing lipid bilayers, free testosterone enters cells via passive diffusion.
- Receptor Activation: Once inside the cell, free testosterone binds to the cytoplasmic androgen receptor (AR). This binding triggers nuclear translocation, where the hormone-receptor complex regulates gene expression.
- Animal Models: Transgenic research shows that even if total testosterone is high, biological activity in target organs is diminished if the free fraction is kept stable, confirming that free testosterone is the actual driver of physiological action.
Tissue signaling and clinical effects
Elevated levels of free testosterone lead to a direct, dose-dependent increase in androgen signaling across various tissues.
- Dose-Response Relationship: In women, research on testosterone replacement therapy shows that supraphysiologic peaks in serum levels (100–250 ng/dL) are strongly correlated with increased tissue signaling. For instance, studies comparing different pellet doses found that higher doses led to a significantly higher incidence of androgenic side effects (57.6% vs. 14.8%).
- Clinical Indicators: High androgen signaling manifests as physical changes such as hirsutism (measured by Ferriman-Gallwey scores), androgenic alopecia, and vocal cord edema.
- Alternative Pathways: While most entry occurs via diffusion, some tissues (like the kidney or prostate) may utilize receptor-mediated endocytosis (megalin/cubilin system) to internalize protein-bound hormones, though this remains an exception to the general rule of free hormone dominance.
Bottom line
Free testosterone is the biologically active fraction that enters cells via passive diffusion to activate androgen receptors. Consequently, elevations in free testosterone directly increase androgen signaling, leading to dose-dependent physiological and clinical effects.
References
- Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis — nature.com
- The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status — pmc.ncbi.nlm.nih.gov
- Novel mechanism of endocrine disruption by fungicides through binding to the membrane androgen receptor, ZIP9 (SLC39A9), and antagonizing rapid testosterone induction of the intrinsic apoptotic pathway. — linkinghub.elsevier.com
- Non-genomic actions of androgens — pmc.ncbi.nlm.nih.gov
- Testosterone Pellets in Women: Revisiting Safety and Clinical Outcomes — cureus.com
- Dysphonia in Cisgender-Females Secondary to Testosterone Therapy. — linkinghub.elsevier.com
- Bilateral ovarian steroid cell tumor in a postmenopausal woman with progressive hyperandrogenism. — academic.oup.com
- Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women — journals.lww.com
- Changes of androgens levels in menopausal women — pmc.ncbi.nlm.nih.gov
- MON-LB002 Compounded Testosterone Preparations Raise Testosterone Levels to Premenopausal Ranges in Postmenopausal Women With Hypo-Sexual Desire Disorder (HSDD) — pmc.ncbi.nlm.nih.gov
See a full patient report verified like this
Book a walkthrough